EVFM Evofem Biosciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1618835 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.0%
TTM net income YoY-133.9%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR9.3%
Net income 3-yr CAGR—
Margins
Gross margin75.9%
Operating margin-16.8%
Net margin-71.7%
FCF margin—
EBITDA margin-16.7%
Returns
ROE—
ROA-120.6%
ROIC (approx.)—
Asset turnover1.68x
Leverage & solvency
Liabilities / assets1,184.7%
Debt / equity—
Current ratio0.07x
Interest coverage-1.18x
Cash quality & payout
Operating cash flow / net income0.05x
Accruals ratio-115.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.63M | $2.63M | $899,000 | $9.56M | $4.95M | $4.83M | $845,000 | $7.10M |
| Cost of revenue | $750,000 | $511,000 | $410,000 | $2.59M | $905,000 | $755,000 | $365,000 | $1.51M |
| Gross profit | $3.88M | $2.12M | $489,000 | $6.97M | $4.05M | $4.07M | $480,000 | $5.59M |
| R&D expense | — | — | — | — | — | — | — | $649,000 |
| SG&A expense | $1.25M | $1.83M | $2.37M | $1.10M | $2.09M | $1.84M | $2.37M | $3.42M |
| Operating income | $740,000 | -$2.49M | -$4.57M | $3.35M | $951,000 | -$1.25M | $327,000 | -$1.00M |
| Interest expense | $682,000 | $626,000 | $614,000 | $606,000 | $599,000 | $588,000 | $577,000 | $570,000 |
| Pretax income | $1.00M | -$11.04M | -$5.47M | $2.79M | -$1.57M | -$1.78M | $956,000 | -$3.04M |
| Income tax | $0 | $0 | -$1,000 | -$1,000 | -$4,000 | $7,000 | — | — |
| Net income | $1.00M | -$11.04M | -$5.46M | $2.79M | -$1.57M | -$1.78M | $956,000 | -$3.04M |
| EBITDA | $743,000 | -$2.48M | -$4.57M | $3.35M | $955,000 | -$1.25M | $333,000 | -$998,000 |
| EPS (basic) | 0.01 | -0.08 | -0.04 | — | -0.01 | -0.01 | 0.01 | — |
| EPS (diluted) | 0.00 | -0.08 | -0.04 | — | -0.01 | -0.01 | 0.00 | — |
| Weighted avg. shares (diluted) | 6.81B | 137.34M | 133.25M | — | 124.39M | 120.49M | 6.16B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $317,000 | $285,000 | $1.49M | $578,000 | $840,000 | $748,000 | $1.11M | $741,000 |
| Receivables | $3.66M | $2.50M | $560,000 | $12.48M | $4.43M | $4.93M | $1.15M | $9.83M |
| Inventory | $1.23M | $2.15M | $1.89M | $1.13M | $1.68M | $1.91M | $2.26M | $1.58M |
| Current assets | $5.96M | $6.08M | $6.06M | $15.28M | $7.92M | $8.97M | $5.87M | $13.61M |
| PP&E, net | $409,000 | $412,000 | $416,000 | $418,000 | $420,000 | $424,000 | $429,000 | $458,000 |
| Intangibles | $762,000 | $869,000 | $778,000 | $4.35M | $5.24M | $4.74M | $6.49M | $9.60M |
| Total assets | $7.26M | $7.52M | $7.44M | $20.27M | $13.81M | $14.38M | $12.88M | $23.79M |
| Current liabilities | $84.78M | $88.61M | $78.75M | $84.82M | $78.19M | $73.89M | $70.85M | $80.45M |
| Short-term debt | $1.01M | $362,000 | — | $147,000 | $291,000 | $383,000 | — | $135,000 |
| Total liabilities | $86.02M | $90.01M | $80.15M | $89.71M | $83.98M | $79.21M | $77.68M | $90.26M |
| Shareholders' equity | -$83.93M | -$87.52M | -$77.63M | -$74.34M | -$75.07M | -$69.62M | -$69.59M | -$71.26M |
| Shares outstanding | 132.53M | 132.53M | 132.53M | 126.69M | 123.96M | 118.66M | 113.36M | 113.36M |
| Cash flow statement | ||||||||
| Operating cash flow | $214,000 | -$3.14M | $2.30M | $31,000 | $336,000 | -$2.92M | $560,000 | -$2.41M |
| Capital expenditure | — | $0 | $2,000 | $3,000 | $0 | — | — | $0 |
| Free cash flow | — | -$3.14M | $2.30M | $28,000 | $336,000 | — | — | -$2.41M |
| Investing cash flow | $0 | $0 | -$2,000 | -$3,000 | $0 | -$2,000 | -$57,000 | -$46,000 |
| Financing cash flow | -$182,000 | $1.05M | -$498,000 | -$290,000 | -$244,000 | $2.56M | -$135,000 | $2.47M |
| Depreciation & amortization | $3,000 | $4,000 | $4,000 | $5,000 | $4,000 | $4,000 | $6,000 | $5,000 |
| Stock-based compensation | $0 | $0 | $15,000 | $42,000 | $23,000 | $31,000 | $70,000 | $188,000 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.